Your browser doesn't support javascript.
loading
Choosing a better end point for trials of bone-protective agents.
Leibowitz-Amit, R; Khoja, L; Tannock, I F; Joshua, A M.
Affiliation
  • Leibowitz-Amit R; Oncology Institute & Cancer Research Center, Sheba Medical Center, Tel-Hashomer, Israel.
  • Khoja L; Princess Margaret Cancer Centre, Toronto, Canada.
  • Tannock IF; Princess Margaret Cancer Centre, Toronto, Canada.
  • Joshua AM; Princess Margaret Cancer Centre, Toronto, Canada. Electronic address: anthony.joshua@uhn.ca.
Ann Oncol ; 26(5): 1032-1033, 2015 May.
Article in En | MEDLINE | ID: mdl-25632065
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Neoplasms / Bone Density Conservation Agents / Prostatic Neoplasms, Castration-Resistant / Denosumab Limits: Humans / Male Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2015 Type: Article Affiliation country: Israel
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bone Neoplasms / Bone Density Conservation Agents / Prostatic Neoplasms, Castration-Resistant / Denosumab Limits: Humans / Male Language: En Journal: Ann Oncol Journal subject: NEOPLASIAS Year: 2015 Type: Article Affiliation country: Israel